Table 3.
Circulating histones and histones complexes in hematologic malignancies.
| Malignancy | Target for Detection | Detection Method |
Level | Suggested Function | Reference |
|---|---|---|---|---|---|
| Leukemia | Histone—dsDNA complex | ELISA | High | Disease progression Chemotherapy resistance |
[115,116] |
| Leukemia | NA | NA | Injection of 200 µg/mL H1 histone |
Cytotoxicity of tumor cells | [117] |
| Burkitt’s lymphoma | NA | NA | Injection of 200 µg/mL H1 histone |
Inhibits tumor growth | [117] |
| Lymphoma | Anti-histone, anti-DNA-antibodies |
ELISA | High | Detection | [118] |
| Non-Hodgkin lymphoma (NHL) |
Nu.Q-H3.1 | ELISA | High | Detection | [119] |
| Acute myeloid leukemia (AML) |
Nu.Q-H3.1 | ELISA | High | Detection | [119] |
| Acute lymphocytic leukemia (ALL) |
Nu.Q-H3.1 | ELISA | High | Detection | [119] |
| AML | Anti-histone, anti-DNA-antibodies |
ELISA | Initial rise + Decrease following treatment |
Chemotherapy response | [121] |
| Lymphoma | UV intensities of individual DNA fragments | Detection on 2% agarose gel |
High | Detection of disease progression | [122] |